<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03976271</url>
  </required_header>
  <id_info>
    <org_study_id>HCIR</org_study_id>
    <nct_id>NCT03976271</nct_id>
  </id_info>
  <brief_title>Consequences of Hypoglycaemia on Cardiovascular and Inflammatory Responses</brief_title>
  <acronym>HCIR</acronym>
  <official_title>Consequences of Hypoglycaemia on Cardiovascular and Inflammatory Responses in Patients With Diabetes Mellitus Type 1, Type 2 and Healthy Volunteers</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Radboud University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Rigshospitalet, Denmark</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Radboud University</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      People with Type 1 diabetes (T1DM), type 2 diabetes (T2DM) and healthy volunteers will
      undergo a hypoglycaemic clamp to to investigate the effect of hypoglycaemia on cardiovascular
      and inflammatory responses.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Objectives: The overall aim of the present study is to investigate the effect of
      hypoglycaemia on cardiovascular and inflammatory responses, molecular mechanisms and
      epigenetic profiles in various groups of people with diabetes type 1, type 2 and healthy
      volunteers.

      Study design: Intervention study

      Intervention: All subjects will undergo a hyperinsulinemic normoglycaemic-hypoglycaemic
      glucose clamp (nadir 2.8 mmol/L), during and after which blood and urine will be sampled for
      further examination for up to one week.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">August 12, 2019</start_date>
  <completion_date type="Anticipated">December 4, 2020</completion_date>
  <primary_completion_date type="Anticipated">October 4, 2020</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Diagnostic</primary_purpose>
    <masking>None (Open Label)</masking>
    <masking_description>All subjects will undergo a hyperinsulinemic normoglycaemic-hypoglycaemic glucose clamp (nadir 2.8 mmol/L), during and after which blood and urine will be sampled for further examination for up to one week.</masking_description>
  </study_design_info>
  <primary_outcome>
    <measure>Inflammatory responses of hypoglycaemia by measuring the cytokine production of isolated monocytes using ELISA</measure>
    <time_frame>1.5 year</time_frame>
    <description>Cytokine production (TNF-alfa, IL-6, IL-10 and IL-1β) of isolated and stimulated monocytes</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Atherogenic responses of (recurrent) hypoglycaemia using foam cell formation.</measure>
    <time_frame>1.5 year</time_frame>
    <description>Measurement of Ox-LDL uptake by measuring intracellular apolipoproteine B</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Metabolomics profile of each group</measure>
    <time_frame>1.5 year</time_frame>
    <description>Un-targeted metabolomics and identification of metabolites based on exact mass using metabolomics library</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Epigenetic modifications</measure>
    <time_frame>1.5 year</time_frame>
    <description>Epigenetic modifications due to hypoglycaemia in the promoter regions of the pro-inflammatory cytokines in monocytes</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cardiac function responses to hypoglycaemia using echocardiography</measure>
    <time_frame>1.5 year</time_frame>
    <description>Cardiac function responses to hypoglycaemia using echocardiography</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cognitive function responses to hypoglycaemia using cognitive function tests (TAP, PASAT)</measure>
    <time_frame>1.5 year</time_frame>
    <description>Amount of correct answers</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Oxidative stress responses using oxidative stress marker</measure>
    <time_frame>1.5 year</time_frame>
    <description>Excretion of guanine nucleosides in urine (ng/mL)</description>
  </secondary_outcome>
  <number_of_arms>6</number_of_arms>
  <enrollment type="Anticipated">112</enrollment>
  <condition>Hypoglycemia</condition>
  <condition>Inflammatory Response</condition>
  <condition>Diabetes Mellitus, Type 1</condition>
  <condition>Diabetes Mellitus, Type 2</condition>
  <arm_group>
    <arm_group_label>T1DM poor glycaemic control</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>patients with type 1 diabetes and poor glycaemic control (HbA1c &gt;8% / &gt;64 mmol/mol will undergo hyperinsulinemic normoglycaemic-hypoglycaemic glucose clamp</description>
  </arm_group>
  <arm_group>
    <arm_group_label>T1DM impaired awareness</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>patients with type 1 diabetes and impaired awareness of hypoglycaemia will undergo hyperinsulinemic normoglycaemic-hypoglycaemic glucose clamp</description>
  </arm_group>
  <arm_group>
    <arm_group_label>T1DM Normal awareness</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>patients with type 1 diabetes and normal awareness of hypoglycaemia will undergo hyperinsulinemic normoglycaemic-hypoglycaemic glucose clamp</description>
  </arm_group>
  <arm_group>
    <arm_group_label>T2DM + Insulin</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>patients with type 2 diabetes with insulin treatment for at least 1 year will undergo hyperinsulinemic normoglycaemic-hypoglycaemic glucose clamp</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Healthy control T2DM</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>healthy controls without diabetes and age, gender and BMI matched with diabetes type 2 participants will undergo hyperinsulinemic normoglycaemic-hypoglycaemic glucose clamp</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Healthy control T1DM</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Healthy controls without diabetes and age, gender and BMI matched with diabetes type 1 participants will undergo hyperinsulinemic normoglycaemic-hypoglycaemic glucose clamp</description>
  </arm_group>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>hyperinsulinemic normoglycaemic-hypoglycaemic glucose clamp</intervention_name>
    <description>For this study, a hyperinsulinemic normoglycaemic-hypoglycaemic glucose clamp will be conducted to investigate the effect of hypoglycaemia. This means that subjects will receive an intravenous insulin infusion, at a continuous rate of 60 mU∙m-2∙min-1, as well as glucose 20% w/w intravenously at a variable rate, adjusted by arterial plasma glucose levels, measured at 5 minute intervals.</description>
    <arm_group_label>Healthy control T1DM</arm_group_label>
    <arm_group_label>Healthy control T2DM</arm_group_label>
    <arm_group_label>T1DM Normal awareness</arm_group_label>
    <arm_group_label>T1DM impaired awareness</arm_group_label>
    <arm_group_label>T1DM poor glycaemic control</arm_group_label>
    <arm_group_label>T2DM + Insulin</arm_group_label>
    <other_name>hypoglycaemic clamp</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

        Overall inclusion criteria

          -  Ability to provide written informed consent

          -  Must be able to speak and read Danish (for Hillerød-site) and Dutch (for
             Nijmegen-site)

          -  Insulin treatment according to basal-bolus insulin regimen (injections or insulin
             pump) (except for group 5)

          -  Body-Mass Index: 19-40 kg/m2

          -  Age ≥18 years, ≤ 80 years

          -  Blood pressure: &lt;140/90 mmHg

          -  Duration of diabetes &gt; 1 year (except for group 5)

          -  HbA1c &lt; 100 mmol/mol

        Group specific

          -  Group 1: HbA1c &gt;64 mmol/mol

          -  Group 2: impaired awareness of hypoglycaemia (IAH) as assessed by a score of ≥3 on the
             modified Clarke questionnaire, ≥4 on the Gold questionnaire and a positive score on
             the Pedersen-Bjergaard questionnaire.

          -  Group 3: normal awareness of hypoglycaemia (NAH) as assessed by a score of &lt;3 on the
             modified Clarke questionnaire, &lt;4 on the Gold questionnaire and a negative score on
             the Pedersen-Bjergaard.

          -  Group 4: Insulin treatment for at least 1 year

          -  Group 5/6: HbA1c &lt;42 mmol/mol

        Exclusion Criteria:

          -  - Severe medical or psychological conditions interfering with the perception of
             hypoglycaemia other than IAH such as brain injuries, epilepsy, a major cardiovascular
             disease event or anxiety disorders

          -  Use of immune-modifying drugs or antibiotics

          -  Treatment with glucose-modifying (other than insulin, SGLT-2 inhibitors and metformin)
             agents (e.g. prednisolon)

          -  Use of anti-depressive drugs

          -  Pregnancy or breastfeeding or unwillingness to undertake measures for birth control

          -  Use of statins (e.g. stop statins &gt;2 weeks before performing blood sampling. This can
             be safely done in the context of primary prevention)

          -  Any event of cardiovascular disease in the past 5 years (e.g. myocardial infarction,
             stroke, heart failure, symptomatic peripheral arterial disease)

          -  Auto-inflammatory or auto-immune diseases

          -  Any infection in past three months

          -  Previous vaccination in the past three months

          -  Laser coagulation for proliferative retinopathy in the past six months

          -  Proliferative retinopathy

          -  Diabetic nephropathy as reflected by an albumin-creatinine ratio ˃ 30 mg/gor an
             estimated glomerular filtration rate (by MDRD) ˂60ml/min/1.73m2

          -  History of pancreatitis (acute or chronic) or pancreatic cancer
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Bastiaan E de Galan, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Radboud University</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Ulrik Pedersen-Bjergaard, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Nordsjællands University Hospital</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Clementine EM Verhulst, MD</last_name>
    <phone>+ 31 24 36 19086</phone>
    <email>clementine.verhulst@radboudumc.nl</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Bastiaan E de Galan, MD, PhD</last_name>
    <phone>+ 31 24 36 13286</phone>
    <email>bastiaan.degalan@radboudumc.nl</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Nordsjællands University Hospital</name>
      <address>
        <city>Hillerød</city>
        <state>Nordsjaelland</state>
        <zip>3400</zip>
        <country>Denmark</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Therese E Wilbek Fabricius, MD</last_name>
      <phone>+ 45 30700175</phone>
      <email>therese.emilie.wilbek.fabricius@regionh.dk</email>
    </contact>
    <contact_backup>
      <last_name>Ulrik Pedersen-Bjergaard, MD, PhD</last_name>
      <phone>+45 48 29 48 10</phone>
      <email>ulrik.pedersen-bjergaard@regionh.dk</email>
    </contact_backup>
    <investigator>
      <last_name>Ulrik Pedersen-Bjergaard, Prof</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Radboudumc</name>
      <address>
        <city>Nijmegen</city>
        <state>Gelderland</state>
        <zip>6525 GA</zip>
        <country>Netherlands</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Clementine EM Verhulst, MD</last_name>
      <phone>+ 31 24 36 19086</phone>
      <email>clementine.verhulst@radboudumc.nl</email>
    </contact>
    <contact_backup>
      <last_name>Bastiaan E de Galan, MD, PhD</last_name>
      <phone>+ 31 24 36 13286</phone>
      <email>bastiaan.degalan@radboudumc.nl</email>
    </contact_backup>
    <investigator>
      <last_name>Bastiaan E de Galan, MD, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Denmark</country>
    <country>Netherlands</country>
  </location_countries>
  <verification_date>September 2019</verification_date>
  <study_first_submitted>November 8, 2018</study_first_submitted>
  <study_first_submitted_qc>June 3, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">June 6, 2019</study_first_posted>
  <last_update_submitted>April 21, 2020</last_update_submitted>
  <last_update_submitted_qc>April 21, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">April 22, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Diabetes Mellitus</mesh_term>
    <mesh_term>Diabetes Mellitus, Type 2</mesh_term>
    <mesh_term>Hypoglycemia</mesh_term>
    <mesh_term>Diabetes Mellitus, Type 1</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hypoglycemic Agents</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
    <ipd_description>No IPD sharing plan necessary</ipd_description>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

